"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at everolimus for neuroendocrine tumours (RADIANT 4)
This trial looked at everolimus (Afinitor) to treat neuroendocrine tumours (NETs) of the digestive system or lungs.
More about this trial
Neuroendocrine tumours (NETs) are a rare group of cancers that develop in the neuroendocrine system. Some make extra hormones and cause symptoms, and others don’t.
This trial was for people who had a NET of the
Everolimus is a type of biological therapy called a cancer growth blocker. We know from research that everolimus helps treat NETs that affect other parts of the body.
The aim of this trial was to find if everolimus could help people with non functioning NETs of the digestive system or lungs.
Summary of results
The team found that everolimus did help people with non functioning NETs of the digestive system or lungs.
This was a phase 3 trial. It was a double blinded randomised trial. Neither the people who took part or their doctor could choose which group they were in. And they also didn’t know which group they were in.
302 people took part.
- 205 had everolimus
- 97 had a dummy drug (
The researchers looked at the average length of time it took for the NET to start growing again. They found it was:
- 11 months for those who had everolimus
- just under 4 months for those who had the dummy drug
The most severe side effects of everolimus were:
- sore mouth
- a drop in red blood cells
- an increased level of sugar in the blood
The trial team concluded that everolimus significantly improved the length of time it took before the NET started to grow again.
The researchers are still following up these people to find out if everolimus increased the length of time people live after treatment. When these results become available we will update this summary.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Juan Valle
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer